For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Embla is now making its approach available to U.S. employers as an alternative to high-dose GLP-1 programs. "GLP-1s are powerful tools, but the tools too often become the treatment. When care is ...

MET-097i, our most advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA that we are ... weekly doses of 1.2 mg and 7.2% after twelve weekly ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical data. The latest results show a high starting dose, fast titration model ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... taking the highest dose of the drug scored ...

The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin ... with GLP-1 RAs would also enable insulin dose reduction and add cardiorenal benefit in ...

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% ...

(HealthDay News) — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA ... Ozempic dose at seven days prior to surgery was identified as an independent risk factor for conversion ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days ... Last Ozempic dose at seven days prior to surgery was identified as an independent risk factor for ...